


REMARKS

Currently claims 1-34 are pending. Applicants amend claims 16, 18, 20, 22, and 30 to remove unintentional duplication and/or to reduce the filing fee by removing multiple dependency. Claims 4, 6, 8, 10-15, 19, 21, and 23-29 are cancelled to remove claims inappropriate to US practice or to reduce the filing fee by reducing the total number of claims. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: 20 Jan 2005

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988